Latest Media Releases

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Immutep announces More mature positive data for TACTI-mel trial presented (ASX:IMM)

SYDNEY, AUSTRALIA – May 17, 2019 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep“ or “the Company“), a biotechnology company developing novel immunotherapy trea...read more

MMJ Group Holdings announces Investment in Volero Brands Inc (ASX:MMJ)

Investment in Volero Brands Inc Canadian manufacturer of the Flyte brand of vape pens and cartridges MMJ Group Holdings Limited (ASX: MMJ) ("MMJ") has invested CAD12.5m for a 7.3% shareh...read more

MMJ announces Net Tangible Asset Backing (ASX:MMJ)

MMJ Group Holdings Limited (ASX: MMJ) ("MMJ") provides its net tangible asset per share (“NTA”) as at 30 April 2019 pursuant to Listing Rule 4.12 as a listed investment company. ...read more

Immutep to present at upcoming industry conferences (ASX:IMM)

SYDNEY, AUSTRALIA – May 10, 2019 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep“ or “the Company“), a biotechnology company developing novel immunotherapy trea...read more

MMJ, Investor Update (ASX:MMJ)

MMJ Group Holdings Limited (ASX:MMJ) ("MMJ") provides an update on MMJ recent activities. Contents 1. Finance News Network Interview with MMJ’s Chief Financial Officer 2. MMJ ...read more

Immutep, Form 603 (ASX:IMM)

Notice of initial substantial holder To view Notice please download PDF attached:

Noxopharm Announces DARRT Six Month Interim Data Shows Lasting Disease Control (ASX:NOX)

Long-lasting responses with Veyonda + low-dose radiotherapy in late-stage prostate cancer High proportion of disease control following a single, short course of treatment Complete resolution ...read more

MMJ Group Holdings, Amended 3Y (ASX:MMJ)

MMJ Group Holdings Limited (ASX:MMJ) ("MMJ") has enclosed an amended 3Y for Mr Doug Halley. The amended 3Y correctly states that Mr. Halley held 130,000 MMJ ordinary shares at B (instead of ...read more

Immutep, Operational Update (ASX:IMM)

Highlights - Recruitment for the AIPAC study expected to be completed in Q2 2019 - 15 patients enrolled in TACTI-002 Phase II collaboration study with MSD - Trial protocol approved for the IN...read more

MMJ Group Holdings, Change of Director’s Interest Notice (ASX:MMJ)

Appendix 3Y Name of entity: Mr Doug Halley Date of last notice: 26 April 2019 To view Notice please download PDF attached:

MMJ Group Holdings, Appendix 3Y (ASX:MMJ)

Change of Director’s Interest Notice Mr Doug Halley To view Notice please download PDF attached:

Imugene Announces New HER-Vaxx Cancer Vaccine Phase Ib trial data to be presented at the American Society of Clinical Oncology 2019 Annual Meeting (ASX:IMU)

SYDNEY, Australia, 29 April 2019: Imugene Limited (ASX:IMU), a clinical stage immuno-oncology company, today announced updated data from the ongoing patients in the Phase Ib study of its HER-Vaxx canc...read more